Blood Detection of EGFR Mutation For Iressa Treatment
Status:
Unknown status
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
This study was proposed to validate the efficacy of gefitinib as first-line therapy in
advanced lung adenocarcinoma with EGFR mutation determined by plasma cf-DNA.